Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based solely on a patient’s cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis provides critical evidence regarding whether standard trauma-focused treatments remain effective in the substantial population of PTSD patients who use cannabis, addressing a gap in clinical guidelines where this patient population is often excluded from efficacy trials. The findings directly inform treatment selection and prognostication for dual-diagnosis patients, who represent a clinically complex group frequently encountered in real-world settings but underrepresented in traditional PTSD treatment literature. Understanding cannabis use as either a moderator of treatment response or a non-limiting factor has immediate implications for individualizing therapy and managing clinician expectations in this high-risk, co-morbid population.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis of individual patient data from Project Harmony addresses a clinically important question about whether trauma-focused treatments remain effective for patients with concurrent cannabis and other substance use, several limitations warrant cautious interpretation. The analysis draws from only four RCTs within a larger pool of 36 studies, which may not fully capture the heterogeneity of cannabis use patterns, dosing, frequency, or cannabinoid profiles that could meaningfully affect treatment outcomes. Additionally, the meta-analytic approach inherently obscures important clinical nuances such as whether cannabis use was active during treatment, whether patients were motivated to reduce use, and the degree to which cannabis may have been self-medication for undertreated PTSD symptoms rather than a primary disorder. From a practical standpoint, these findings suggest that active cannabis use should not be an automatic contraindication to engaging patients with PTSD and co-occurring substance disorders in evidence-based trauma-focused treatment, though clinicians should maintain realistic expectations about engagement and completion rates while simultaneously addressing substance